Premium
Update on actinic keratosis in clinical trial experience with imiquimod
Author(s) -
Ferrándiz C.
Publication year - 2007
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2007.08270.x
Subject(s) - imiquimod , actinic keratosis , medicine , dermatology , actinic keratoses , tolerability , ablative case , basal cell , keratosis , lesion , surgery , pathology , adverse effect , radiation therapy
Actinic keratoses (AK) is a sun induced cutaneous lesion, currently considered as a squamous cell carcinoma in situ that has the potential to progress to invasive SCC. To treat them, numerous, ablative and no ablative, therapeutic approaches exist. Among them, imiquimod, a toll like receptor agonist, recently approved to treat them in the US and Europe, has demonstrated to be effective and safe with an acceptable tolerability in the treatment of these lesions. In this article the results of several high quality RCT are analysed.